Coologics
6 known investors
Coologics develops a drug-free medical device designed to treat vaginal yeast and bacterial infections through controlled cooling technology. The device targets women seeking non-pharmaceutical relief and clinical cure from recurrent infections.
Also known as Coologics Inc. · Coologics, Inc.
Investors · 6
Also in the syndicate · 4
Company profile
researched Aug 2026Coologics Inc. is a clinical-stage medical device company based in Cleveland, Ohio, developing Vlisse, a drug-free intravaginal device that uses a patented controlled-cooling mechanism to treat vaginal infections. The company positions Vlisse as an alternative to antifungal and antibiotic therapy for vulvovaginal candidiasis (VVC), bacterial vaginosis (BV) and mixed infections, with the stated aim of restoring the vaginal environment to a healthy state without chemicals and reducing contributions to antibiotic resistance.
Vlisse is a tampon-like investigational device that the company says is being evaluated for the management of vaginal yeast infections, supported by published peer-reviewed data in human and mouse models and a preliminary published pilot study reporting symptom relief and clinical cure. Coologics states that Vlisse is pursuing FDA clearance in the United States as a De Novo Class II medical device, and that proceeds from its 2025 seed round are directed at completing an ongoing clinical trial, making an FDA submission and an initial market release.
The company is led by founder and CEO/President Dr. Kim Langdon, an OB/GYN described as having experienced recurrent infections and a preterm birth herself, alongside Chief Medical Officer Dr. Nicole E. Williams; Rich Mazzola serves as CFO. Langdon is an Ohio State University alumna and Williams a University of Illinois alumna, links reflected in the alumni investor groups that participated in the seed round.
Founding story
The device was invented by a female OB/GYN who is herself a recurrent sufferer of vaginal infections and had a preterm birth, with the company describing the product as designed from both clinical and patient perspectives.
Business model
Pre-commercial medical device company developing a proprietary, patented device (Vlisse) intended for sale following regulatory clearance; the company is funded by venture and angel investment while it completes clinical work and prepares an initial market release.
No product revenue disclosed; the company is pre-clearance and pre-launch, with planned revenue from sales of the Vlisse device after regulatory clearance.
Traction
A preliminary published pilot study of the investigational device reported early potential for symptom relief and clinical cure; a clinical trial was ongoing as of April 2025. The company had raised more than $3 million in an oversubscribed seed round with institutional and university alumni investors.
Latest developments
In April 2025 Coologics announced the closing of an oversubscribed seed round of more than $3 million, led by Prevail Ventures and Dream Ventures with participation from the Ohio State Early Investor Network and Illinois Ventures' Illini Angels Program. Capital is earmarked for completing the ongoing clinical trial, an FDA submission and initial market release of Vlisse.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
An early-stage entrant in women's health devices addressing vaginal yeast and bacterial infections. Sources cite market context including more than 6.5 million U.S. women with non-healing vaginal infections, roughly $50 billion in annual associated healthcare costs, and over $14 billion in annual lost productivity from recurrent infections.
Coologics' approach is non-pharmaceutical: rather than antifungal or antibiotic drugs, Vlisse applies patented controlled cooling intravaginally, which the company says avoids drug-related side effects and pharmacological interactions and reduces contributions to antibiotic resistance. The company cites published, peer-reviewed human and mouse data and a preliminary pilot study as early validation, and physician-founder clinical insight as a further differentiator.
Technology
A patented controlled-cooling technology delivered via a tampon-like intravaginal device. The cooling mechanism is intended to treat vulvovaginal candidiasis, bacterial vaginosis and mixed infections and to restore the vaginal environment without drugs or chemicals. The company references published peer-reviewed data in human and mouse models.
Go-to-market
The company communicates with investors, providers, patients and clinical trial partners through its website and press releases, and maintains a notification list for milestones such as FDA submissions and approvals; commercial rollout is planned to follow clinical trial completion and FDA submission.
Women experiencing vaginal yeast infections, bacterial vaginosis and mixed or recurrent infections, including those seeking non-drug options; secondary audiences are OB/GYNs and other clinicians, and clinical research partners.
Geography
Headquartered in Cleveland, Ohio, United States, with regulatory activity focused on FDA clearance in the U.S. market.
History
Coologics was founded by Dr. Kim Langdon, an OB/GYN, and is co-founded with Dr. Nicole Williams according to regional coverage. In April 2025 the company announced the closing of an oversubscribed seed round of more than $3 million, exceeding an initial $1.5 million target, to fund completion of its ongoing clinical trial, FDA submission and initial market release of Vlisse.
Risks & controversies
Vlisse remains an investigational device and has not received FDA clearance; the company is pursuing a De Novo Class II pathway, and its milestones depend on completing an ongoing clinical trial and an FDA submission. Clinical evidence to date is described as preliminary pilot and preclinical data.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsCoologics announced the closing of an oversubscribed seed round securing over $3 million, exceeding an initial target of $1.5 million. Led by Prevail Ventures and Dream Ventures, with participation from the Ohio State Early Investor Network and Illinois Ventures' Illini Angels Program. Proceeds are for completing the ongoing clinical trial, FDA submission and initial market release of Vlisse.
$3M source ↗
Coologics states that Vlisse is pursuing FDA clearance in the U.S. as a De Novo Class II medical device and remains an investigational device under clinical evaluation.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Coologicscoologics.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Coologics do?
- Cleveland-based clinical-stage medical device company developing Vlisse, a drug-free intravaginal cooling device for vaginal infections.
- Who are Coologics's investors?
- Coologics's investors include Illinois Ventures, JumpStart Equity.